<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733249</url>
  </required_header>
  <id_info>
    <org_study_id>BP-404</org_study_id>
    <nct_id>NCT03733249</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study</brief_title>
  <official_title>Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term follow up study evaluating the safety of BPX-501 T cells
      (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled on the BP-004 study who have completed 6 months active treatment with
      BPX-501 T-cells (rivogenlecleucel) will be requested to enroll on this long-term follow up
      protocol. Long term follow up for gene therapy clinical and safety endpoints will continue up
      to 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">June 2035</completion_date>
  <primary_completion_date type="Anticipated">June 2034</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>two years after rivogenlecleucel infusion</time_frame>
    <description>Incidence of disease free survival at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 15 years after rivogenlecleucel infusion</time_frame>
    <description>Incidence of delayed adverse events suspected to be related to rivogenlecleucel or rimiducid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with replication competent retrovirus</measure>
    <time_frame>every 6 months after rivogenlecleucel infusion for 5 years and yearly thereafter for another 10 years</time_frame>
    <description>Presence of replication competent retrovirus in patient peripheral blood mononuclear cells measured by quantitative PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector copy number</measure>
    <time_frame>every 6 months after rivogenlecleucel infusion for 5 years and yearly thereafter for another 10 years</time_frame>
    <description>Copy number of integrated retroviruses in patient peripheral blood mononuclear cells measured by quantitative PCR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">193</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Leukemia, Acute Myeloid (AML), Child</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Primary Immunodeficiency</condition>
  <condition>Anemia, Aplastic</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Cytopenia</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Diamond Blackfan Anemia</condition>
  <condition>Thalassemia</condition>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Rimiducid and Rivogenlecleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)
No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimiducid</intervention_name>
    <description>Rimiducid is administered to treat chronic graft versus host disease</description>
    <arm_group_label>Rimiducid and Rivogenlecleucel</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rivogenlecleucel</intervention_name>
    <description>donor T-cells modified with iCasp safety switch</description>
    <arm_group_label>Rimiducid and Rivogenlecleucel</arm_group_label>
    <other_name>BPX-501</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent by the patient or the patient's guardian for children
             who are minors

          -  Enrolled on BP-004 protocol, received BPX-501 infusion and completed 6 months of
             active treatment

        Exclusion Criteria:

          -  Lack of parents'/guardian's informed consent for children who are minors

          -  Loss of allograft prior to 6 months

          -  Progression of malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah International Medical Research Center (KAIMRC)</name>
      <address>
        <city>Riyadh</city>
        <zip>11426</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health &amp; Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great North Children's Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long term follow up</keyword>
  <keyword>Gene-modified cells</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>hematologic neoplasms</keyword>
  <keyword>hematologic malignancies</keyword>
  <keyword>anemia</keyword>
  <keyword>congenital cytopenia</keyword>
  <keyword>primary immune deficiencies</keyword>
  <keyword>hemoglobinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

